Your browser doesn't support javascript.
loading
Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells.
Sugata, Kenji; Matsunaga, Yukiko; Yamashita, Yuki; Nakatsugawa, Munehide; Guo, Tingxi; Halabelian, Levon; Ohashi, Yota; Saso, Kayoko; Rahman, Muhammed A; Anczurowski, Mark; Wang, Chung-Hsi; Murata, Kenji; Saijo, Hiroshi; Kagoya, Yuki; Ly, Dalam; Burt, Brian D; Butler, Marcus O; Mak, Tak W; Hirano, Naoto.
Afiliação
  • Sugata K; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Matsunaga Y; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Yamashita Y; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Nakatsugawa M; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Guo T; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Halabelian L; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Ohashi Y; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Saso K; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Rahman MA; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Anczurowski M; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Wang CH; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Murata K; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Saijo H; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Kagoya Y; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Ly D; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Burt BD; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Butler MO; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Mak TW; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Hirano N; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Nat Biotechnol ; 39(8): 958-967, 2021 08.
Article em En | MEDLINE | ID: mdl-33649568
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coloração e Rotulagem / Antígenos de Histocompatibilidade Classe II / Antígenos HLA Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coloração e Rotulagem / Antígenos de Histocompatibilidade Classe II / Antígenos HLA Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article